Rucsandra Dobrota
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rucsandra Dobrota has a total of 149 co-authors. Here are the top co-authors by number of shared publications:
- Oliver Distler
Department of Rheumatology University Hospital Zurich, University of Zurich Zurich Switzerland
18 shared publications - Carina Mihai
Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
9 shared publications - Mike Oliver Becker
Department of Rheumatology, University Hospital Zurich, University of Zurich , Zurich
7 shared publications - Muriel Elhai
Department of Rheumatology, University Hospital Zurich, University of Zurich , Zurich
7 shared publications Suzana Jordan
Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
7 shared publications- Cosimo Bruni
Department of Rheumatology, University Hospital Zurich, University of Zurich , Zurich
6 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by Springer Nature in Arthritis Research & Therapy
Demographic and clinical features of systemic sclerosis patients with anti-U1RNP antibodies: an European Scleroderma Trials and Research (EUSTAR) analysis
Objective: To investigate the demographic and clinical features of systemic sclerosis (SSc) patients with anti-U1RNP antibodies using the European Scleroderma Trials and Research (EUSTAR) database, a phenotype less well-defined in SSc than other more commonly associated antibodies. Methods: SSc patients fulfilling classification criteria with available data on anti-U1RNP antibodies were analyzed. Clinical characteristics were collected when the status of anti-U1RNP antibodies was first recorded and patients positive/negative for anti-U1RNP antibodies were compared by univariable analysis. Associations between anti-U1RNP status and organ involvement were assessed by multivariable logistic regression. Multiple imputation used for missing data. Results: A total of 8391 patients were eligible for this analysis, among which 408 (4.9%) were positive for anti-U1RNP antibodies. By multivariable analysis, anti-U1RNP antibodies were confirmed independently associated with younger age at disease onset (OR 0.96, 95% CI 0.95 to 0.97), synovitis (OR 1.82, 95% CI 1.20 to 2.77), pulmonary hypertension on echocardiography (OR 2.13, 95% CI 1.41 to 3.20), proteinuria (OR 2.25, 95% CI 1.29 to 3.93), lower mRSS (OR 0.95, 95% CI 0.93 to 0.98) and elevated ESR (OR 1.48, 95% CI 1.03 to 2.12). There was a negative association with White patients (OR 0.25, 95% CI 0.17 to 0.37). Conclusion: This is the largest cohort of SSc patients positive for anti-U1RNP antibodies reported. It defines a distinct clinical phenotype, with predilection for non-white race, younger disease onset, more inflammatory and musculoskeletal, cardiopulmonary or renal involvement. The detection of anti-U1RNP antibodies in SSc patients might be helpful for risk stratification in clinical practice.
- 22 September 2026
- Published by Springer Nature in Arthritis Research & Therapy
Open AccessDemographic and clinical features of systemic sclerosis patients with anti-U1RNP antibodies: an European Scleroderma Trials and Research (EUSTAR) analysis
Objective: To investigate the demographic and clinical features of systemic sclerosis (SSc) patients with anti-U1RNP antibodies using the European Scleroderma Trials and Research (EUSTAR) database, a phenotype less well-defined in SSc than other more commonly associated antibodies. Methods: SSc patients fulfilling classification criteria with available data on anti-U1RNP antibodies were analyzed. Clinical characteristics were collected when the status of anti-U1RNP antibodies was first recorded and patients positive/negative for anti-U1RNP antibodies were compared by univariable analysis. Associations between anti-U1RNP status and organ involvement were assessed by multivariable logistic regression. Multiple imputation used for missing data. Results: A total of 8391 patients were eligible for this analysis, among which 408 (4.9%) were positive for anti-U1RNP antibodies. By multivariable analysis, anti-U1RNP antibodies were confirmed independently associated with younger age at disease onset (OR 0.96, 95% CI 0.95 to 0.97), synovitis (OR 1.82, 95% CI 1.20 to 2.77), pulmonary hypertension on echocardiography (OR 2.13, 95% CI 1.41 to 3.20), proteinuria (OR 2.25, 95% CI 1.29 to 3.93), lower mRSS (OR 0.95, 95% CI 0.93 to 0.98) and elevated ESR (OR 1.48, 95% CI 1.03 to 2.12). There was a negative association with White patients (OR 0.25, 95% CI 0.17 to 0.37). Conclusion: This is the largest cohort of SSc patients positive for anti-U1RNP antibodies reported. It defines a distinct clinical phenotype, with predilection for non-white race, younger disease onset, more inflammatory and musculoskeletal, cardiopulmonary or renal involvement. The detection of anti-U1RNP antibodies in SSc patients might be helpful for risk stratification in clinical practice.
- Open Access
- 27 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (9)
Radiomic analysis of high-resolution computed tomography predicts interstitial lung disease progression and mortality in systemic sclerosis
Objective: The automated assessment of chest high-resolution CT (HRCT) scans allows the objective quantification of interstitial lung disease (ILD)–related features. Here, we explored the ability of HRCT-derived radiomic features to predict all-cause mortality and ILD progression in SSc-ILD patients. Methods: We analysed baseline and follow-up HRCT scans of SSc-ILD patients using lung texture analysis (LTA™, Imbio). Lung parenchymal alterations (honeycombing, ground-glass, reticulation, hyperlucency) and pulmonary vessel volume (PVV) were quantified as percentages of the respective lung volume—for whole lungs and for upper, middle and lower zones. Univariable and multivariable Cox regression and generalized estimating equation (GEE) models were applied to identify radiomics predictors of all-cause mortality and ILD progression, respectively. Results: Of 313 SSc-ILD patients, 267 (85%) were eligible for radiomic analysis and were included in the mortality analysis; 160 (60%) were included in the progression analysis. Over 42 [interquartile range (IQ)R 27–110] months of follow-up, 65 (24%) patients died. They presented with a greater extent of PVV% and parenchymal alterations across all lung zones, compared with patients who survived. PVV% independently predicted mortality [adjusted hazard ratio (HR) 1.21, 95% CI 1.094–1.354], particularly in the upper zones (adjusted HR 1.28, 95% CI 1.11–1.46). Among 261 yearly follow-up visits from 160 SSc-ILD patients, 50.6% showed at least one episode of ILD progression, for a total of 99 (37.7%) episodes. Baseline radiomic features were overall comparable between progressors and non-progressors. The extent of whole-lung honeycombing was identified as the only independent radiomic predictor of ILD progression [adjusted odds ratio 1.53, 95% CI 1.17–2.01]. Conclusion: The PVV% and the extent of honeycombing independently predict mortality and ILD progression, respectively. These radiomic features might support risk stratification of SSc-ILD patients, on top of functional and clinical characteristics.
- 27 August 2026
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 65 (9)
Open AccessRadiomic analysis of high-resolution computed tomography predicts interstitial lung disease progression and mortality in systemic sclerosis
Objective: The automated assessment of chest high-resolution CT (HRCT) scans allows the objective quantification of interstitial lung disease (ILD)–related features. Here, we explored the ability of HRCT-derived radiomic features to predict all-cause mortality and ILD progression in SSc-ILD patients. Methods: We analysed baseline and follow-up HRCT scans of SSc-ILD patients using lung texture analysis (LTA™, Imbio). Lung parenchymal alterations (honeycombing, ground-glass, reticulation, hyperlucency) and pulmonary vessel volume (PVV) were quantified as percentages of the respective lung volume—for whole lungs and for upper, middle and lower zones. Univariable and multivariable Cox regression and generalized estimating equation (GEE) models were applied to identify radiomics predictors of all-cause mortality and ILD progression, respectively. Results: Of 313 SSc-ILD patients, 267 (85%) were eligible for radiomic analysis and were included in the mortality analysis; 160 (60%) were included in the progression analysis. Over 42 [interquartile range (IQ)R 27–110] months of follow-up, 65 (24%) patients died. They presented with a greater extent of PVV% and parenchymal alterations across all lung zones, compared with patients who survived. PVV% independently predicted mortality [adjusted hazard ratio (HR) 1.21, 95% CI 1.094–1.354], particularly in the upper zones (adjusted HR 1.28, 95% CI 1.11–1.46). Among 261 yearly follow-up visits from 160 SSc-ILD patients, 50.6% showed at least one episode of ILD progression, for a total of 99 (37.7%) episodes. Baseline radiomic features were overall comparable between progressors and non-progressors. The extent of whole-lung honeycombing was identified as the only independent radiomic predictor of ILD progression [adjusted odds ratio 1.53, 95% CI 1.17–2.01]. Conclusion: The PVV% and the extent of honeycombing independently predict mortality and ILD progression, respectively. These radiomic features might support risk stratification of SSc-ILD patients, on top of functional and clinical characteristics.
- Top Cited PapersOpen Access
- 17 January 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (4) , 669-679
The incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)
- 17 January 2026
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (4) , 669-679
Top Cited PapersOpen AccessThe incidence of interstitial lung disease in patients with systemic sclerosis: rate, risk factors and prognostic implications in a EUSTAR cohort analysis (CP 133)
- Open Access
- 26 August 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e77108
Multimodal Noninvasive Assessment of C-Reactive Protein for Systemic Inflammation in Adults: Cross-Sectional Study
Background: Accurate and accessible measurements of inflammatory biomarkers are crucial for the diagnosis and monitoring of inflammatory diseases. The gold-standard C-reactive protein (CRP) requires venipuncture, which, despite providing high-quality samples, can cause discomfort, anxiety, and pain, particularly in vulnerable populations such as older patients. It is also resource-intensive, is unsuitable for remote or at-home use, and lacks continuous monitoring capability. These limitations limit patient autonomy and self-management, potentially leading to poorer prognosis due to delays in assessment and medical treatments. As digital health technologies advance, there is increasing interest in leveraging digital biomarkers for remote and real-time monitoring of systemic inflammation. Digital biomarkers derived from noninvasive biofluids could provide a scalable solution for tracking inflammatory status, offering a patient-centered alternative to traditional blood-based assessments. To date, however, there is no consensus on the most suitable modality for assessment or its digitization potential. Therefore, a comprehensive evaluation of the feasibility, reliability, and patient acceptability toward noninvasive, digital inflammatory biomarkers is needed. Objective: Our aim is to evaluate the feasibility of various noninvasive methods to assess inflammatory markers and identify the optimal modality for predicting serum CRP levels. Methods: Inflammatory biomarkers were assessed in 20 participants (10 patients with systemic inflammation defined as a CRP level >5 mg/L and 10 controls) using 6 noninvasive samples (urine, sweat, saliva, exhaled breath, core body temperature, and stool samples) alongside serum samples. Patient preferences were retrieved via a questionnaire. Mann-Whitney U test, Spearman correlation, and all-subset regression were conducted to assess the relationships between serum and nonserum biomarkers and identify optimal predictive models for serum CRP levels. Results: CRP levels were significantly elevated in the inflammation group compared to controls in urine (median 4.5, IQR 4.15‐10.3 vs median 0.69, IQR 0.24‐1.39 μg/mmol; P=.001) and saliva (median 4910, IQR 2735-13,275 vs median 473, IQR 309-700 pg/mL; P=.001). Urine and saliva CRP levels strongly correlated with serum CRP (rsp=0.886; P<.001; rsp=0.709; P<.001). The multimodal model using urine and saliva CRP predicted serum CRP levels with 76.1% outperforming single-modality models. Patients favored urine and saliva tests over blood tests. Conclusions: Urine and saliva represent promising noninvasive alternatives to traditional blood tests for assessing CRP, enabling more accessible and less invasive diagnostic and monitoring approaches.
- 26 August 2025
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 9, e77108
Open AccessMultimodal Noninvasive Assessment of C-Reactive Protein for Systemic Inflammation in Adults: Cross-Sectional Study
Background: Accurate and accessible measurements of inflammatory biomarkers are crucial for the diagnosis and monitoring of inflammatory diseases. The gold-standard C-reactive protein (CRP) requires venipuncture, which, despite providing high-quality samples, can cause discomfort, anxiety, and pain, particularly in vulnerable populations such as older patients. It is also resource-intensive, is unsuitable for remote or at-home use, and lacks continuous monitoring capability. These limitations limit patient autonomy and self-management, potentially leading to poorer prognosis due to delays in assessment and medical treatments. As digital health technologies advance, there is increasing interest in leveraging digital biomarkers for remote and real-time monitoring of systemic inflammation. Digital biomarkers derived from noninvasive biofluids could provide a scalable solution for tracking inflammatory status, offering a patient-centered alternative to traditional blood-based assessments. To date, however, there is no consensus on the most suitable modality for assessment or its digitization potential. Therefore, a comprehensive evaluation of the feasibility, reliability, and patient acceptability toward noninvasive, digital inflammatory biomarkers is needed. Objective: Our aim is to evaluate the feasibility of various noninvasive methods to assess inflammatory markers and identify the optimal modality for predicting serum CRP levels. Methods: Inflammatory biomarkers were assessed in 20 participants (10 patients with systemic inflammation defined as a CRP level >5 mg/L and 10 controls) using 6 noninvasive samples (urine, sweat, saliva, exhaled breath, core body temperature, and stool samples) alongside serum samples. Patient preferences were retrieved via a questionnaire. Mann-Whitney U test, Spearman correlation, and all-subset regression were conducted to assess the relationships between serum and nonserum biomarkers and identify optimal predictive models for serum CRP levels. Results: CRP levels were significantly elevated in the inflammation group compared to controls in urine (median 4.5, IQR 4.15‐10.3 vs median 0.69, IQR 0.24‐1.39 μg/mmol; P=.001) and saliva (median 4910, IQR 2735-13,275 vs median 473, IQR 309-700 pg/mL; P=.001). Urine and saliva CRP levels strongly correlated with serum CRP (rsp=0.886; P<.001; rsp=0.709; P<.001). The multimodal model using urine and saliva CRP predicted serum CRP levels with 76.1% outperforming single-modality models. Patients favored urine and saliva tests over blood tests. Conclusions: Urine and saliva represent promising noninvasive alternatives to traditional blood tests for assessing CRP, enabling more accessible and less invasive diagnostic and monitoring approaches.
- Open Access
- 7 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Towards Digital Biomarkers of Systemic Inflammation Using a Multi-modal Approach: A Feasibility Study (Preprint)
BACKGROUND Accurate and accessible measurements of inflammatory biomarkers are crucial for the diagnosis and monitoring of inflammatory diseases. The gold-standard C-reactive protein (CRP) requires venipuncture, which, despite providing high-quality samples, can cause discomfort, anxiety, and pain, particularly in vulnerable populations such as elderly patients. It is also resource intensive, unsuitable for remote or at-home use, and lacks continuous monitoring capability. These limitations limit patient autonomy and self-management, potentially leading to poorer prognosis due to delays in assessment and medical treatments. As digital health technologies advance, there is increasing interest in leveraging digital biomarkers for remote and real-time monitoring of systemic inflammation (SI). Digital biomarkers derived from non-invasive biofluids could provide a scalable solution for tracking inflammatory status, offering a patient-centered alternative to traditional blood-based assessments. To date, however, there is no consensus on the most suitable modality for assessment or its digitization potential. Therefore, a comprehensive evaluation of the feasibility, reliability, and patient acceptability towards non-invasive, digital inflammatory biomarkers is needed. OBJECTIVE Our aim is to evaluate the feasibility of various non-invasive methods to assess inflammatory markers and identify the optimal modality for predicting serum CRP levels. METHODS Inflammatory biomarkers were assessed in 20 participants (10 patients with SI defined as a CRP level >5 mg/l and 10 controls) using six non-invasive samples (urine, sweat, saliva, exhaled breath, core body temperature, and stool samples) alongside serum samples. Patient preferences were retrieved via a questionnaire. Mann-Whitney U test, Spearman’s correlation, and all-subset regression were conducted to assess the relationships between serum and non-serum biomarkers and to identify optimal predictive models for serum CRP levels. RESULTS CRP levels were significantly elevated in the inflammation group compared to controls in urine (median: 4.5 vs. 0.69 μg/mmol, p=0.001) and saliva (median: 4910 vs. 473 pg/ml, p=0.001). Urine and saliva CRP levels strongly correlated with serum CRP (rsp=0.886, p<0.001; rsp=0.709, p=0.0006). The multi-modal model using urine and saliva CRP predicted serum CRP levels with 76.1% outperforming single-modality models. Patient favored urine and saliva tests over blood tests. CONCLUSIONS Urine and saliva represent promising non-invasive alternatives to traditional blood tests for assessing CRP, enabling more accessible and less invasive diagnostic and monitoring approaches.
- 7 May 2025
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessTowards Digital Biomarkers of Systemic Inflammation Using a Multi-modal Approach: A Feasibility Study (Preprint)
BACKGROUND Accurate and accessible measurements of inflammatory biomarkers are crucial for the diagnosis and monitoring of inflammatory diseases. The gold-standard C-reactive protein (CRP) requires venipuncture, which, despite providing high-quality samples, can cause discomfort, anxiety, and pain, particularly in vulnerable populations such as elderly patients. It is also resource intensive, unsuitable for remote or at-home use, and lacks continuous monitoring capability. These limitations limit patient autonomy and self-management, potentially leading to poorer prognosis due to delays in assessment and medical treatments. As digital health technologies advance, there is increasing interest in leveraging digital biomarkers for remote and real-time monitoring of systemic inflammation (SI). Digital biomarkers derived from non-invasive biofluids could provide a scalable solution for tracking inflammatory status, offering a patient-centered alternative to traditional blood-based assessments. To date, however, there is no consensus on the most suitable modality for assessment or its digitization potential. Therefore, a comprehensive evaluation of the feasibility, reliability, and patient acceptability towards non-invasive, digital inflammatory biomarkers is needed. OBJECTIVE Our aim is to evaluate the feasibility of various non-invasive methods to assess inflammatory markers and identify the optimal modality for predicting serum CRP levels. METHODS Inflammatory biomarkers were assessed in 20 participants (10 patients with SI defined as a CRP level >5 mg/l and 10 controls) using six non-invasive samples (urine, sweat, saliva, exhaled breath, core body temperature, and stool samples) alongside serum samples. Patient preferences were retrieved via a questionnaire. Mann-Whitney U test, Spearman’s correlation, and all-subset regression were conducted to assess the relationships between serum and non-serum biomarkers and to identify optimal predictive models for serum CRP levels. RESULTS CRP levels were significantly elevated in the inflammation group compared to controls in urine (median: 4.5 vs. 0.69 μg/mmol, p=0.001) and saliva (median: 4910 vs. 473 pg/ml, p=0.001). Urine and saliva CRP levels strongly correlated with serum CRP (rsp=0.886, p<0.001; rsp=0.709, p=0.0006). The multi-modal model using urine and saliva CRP predicted serum CRP levels with 76.1% outperforming single-modality models. Patient favored urine and saliva tests over blood tests. CONCLUSIONS Urine and saliva represent promising non-invasive alternatives to traditional blood tests for assessing CRP, enabling more accessible and less invasive diagnostic and monitoring approaches.
- Open Access
How to build a framework to establish a patient research partner network in rheumatology research: a report of a 2-year implementation project
Background: Patient research partners (PRPs) are people living with a relevant disease who actively contribute to research. Their contribution is beneficial for any research project. Although the inclusion of PRPs in rheumatology research is increasingly recommended, its practical implementation, particularly in translational research, remains limited . Enhancing PRP engagement requires a clear understanding of the necessary steps. Objective: This study aims to show steps to achieve successful collaboration between PRPs and researchers in clinical and transitional research in rheumatology. Methods: We established a PRP network by following five main steps: setting up infrastructure, recruitment, training, PRP involvement at an early stage, and ongoing support. We adhered to overall principles of openness, feedback, and regular evaluations to create a respectful and collaborative environment. The initiative was qualitatively assessed via an online questionnaire developed by each six researchers and PRPs. Results: Communicating our initiative at laboratory open days and to patient associations has enabled to create a network of 66 PRPs. A match-making tool was introduced to allocate interested PRPs with a project request. This led to PRP involvement in 15 projects, including 9 in translational research. Two PRP-coordinators provided support including glossaries and educational courses . Conclusion: Our initiative outlines five essential steps for establishing PRP collaboration in rheumatology research, including translational research. This approach benefited both PRPs and researchers and might serve as a guide for other centres.
Open AccessHow to build a framework to establish a patient research partner network in rheumatology research: a report of a 2-year implementation project
Background: Patient research partners (PRPs) are people living with a relevant disease who actively contribute to research. Their contribution is beneficial for any research project. Although the inclusion of PRPs in rheumatology research is increasingly recommended, its practical implementation, particularly in translational research, remains limited . Enhancing PRP engagement requires a clear understanding of the necessary steps. Objective: This study aims to show steps to achieve successful collaboration between PRPs and researchers in clinical and transitional research in rheumatology. Methods: We established a PRP network by following five main steps: setting up infrastructure, recruitment, training, PRP involvement at an early stage, and ongoing support. We adhered to overall principles of openness, feedback, and regular evaluations to create a respectful and collaborative environment. The initiative was qualitatively assessed via an online questionnaire developed by each six researchers and PRPs. Results: Communicating our initiative at laboratory open days and to patient associations has enabled to create a network of 66 PRPs. A match-making tool was introduced to allocate interested PRPs with a project request. This led to PRP involvement in 15 projects, including 9 in translational research. Two PRP-coordinators provided support including glossaries and educational courses . Conclusion: Our initiative outlines five essential steps for establishing PRP collaboration in rheumatology research, including translational research. This approach benefited both PRPs and researchers and might serve as a guide for other centres.
- Open Access
Validation of a semi-quantitative method to assess interstitial lung disease severity and progression in systemic sclerosis by standard and low-dose HRCT scans
Background: While the presence of distinct imaging abnormalities by high-resolution CT (HRCT) defines interstitial lung disease (ILD), there is a relative lack of validated methods to quantify these abnormalities in clinical practice, limiting ILD severity and progression assessments. We aimed to validate a semi-quantitative method for lung fibrosis assessment in patients with systemic sclerosis associated ILD (SSc-ILD) by standard and low-dose HRCT, considering lung structure and function as integral components of ILD evaluation. Methods: SSc patients from Oslo and Zurich with HRCT images, pulmonary function tests, including forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO) and the 6-minute walk test with oxygen (O2) desaturation were enrolled. We validated the semi-quantitative fibrosis extent method by HRCT using criteria for content and construct validity, discrimination, sensitivity to change and feasibility, as well as inter- and intra-rater variability. Results: 65 SSc patients from Zurich and 90 from Oslo were included. Significant correlations were observed between the extent of fibrosis on HRCT and FVC (r=−0.517, p2 desaturation (r=−0.500, p2 desaturation. Inter- and intra-rater variability demonstrated excellent reliability (κ=0.891 and κ=0.996, respectively), with HRCT quantification averaging 9–15 min, indicating high feasibility. Conclusion: This study confirms that semi-quantitative fibrosis assessment of HRCT for SSc-ILD meets most validation criteria, supporting its use in clinical practice and showing additive value of structural to functional ILD assessment.
Open AccessValidation of a semi-quantitative method to assess interstitial lung disease severity and progression in systemic sclerosis by standard and low-dose HRCT scans
Background: While the presence of distinct imaging abnormalities by high-resolution CT (HRCT) defines interstitial lung disease (ILD), there is a relative lack of validated methods to quantify these abnormalities in clinical practice, limiting ILD severity and progression assessments. We aimed to validate a semi-quantitative method for lung fibrosis assessment in patients with systemic sclerosis associated ILD (SSc-ILD) by standard and low-dose HRCT, considering lung structure and function as integral components of ILD evaluation. Methods: SSc patients from Oslo and Zurich with HRCT images, pulmonary function tests, including forced vital capacity (FVC), diffusing capacity for carbon monoxide (DLCO) and the 6-minute walk test with oxygen (O2) desaturation were enrolled. We validated the semi-quantitative fibrosis extent method by HRCT using criteria for content and construct validity, discrimination, sensitivity to change and feasibility, as well as inter- and intra-rater variability. Results: 65 SSc patients from Zurich and 90 from Oslo were included. Significant correlations were observed between the extent of fibrosis on HRCT and FVC (r=−0.517, p2 desaturation (r=−0.500, p2 desaturation. Inter- and intra-rater variability demonstrated excellent reliability (κ=0.891 and κ=0.996, respectively), with HRCT quantification averaging 9–15 min, indicating high feasibility. Conclusion: This study confirms that semi-quantitative fibrosis assessment of HRCT for SSc-ILD meets most validation criteria, supporting its use in clinical practice and showing additive value of structural to functional ILD assessment.
- Open Access
Performance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis
Objective Systemic sclerosis Impact of Disease (ScleroID) is the first comprehensive patient-reported outcome measure (PROM) specifically developed for systemic sclerosis (SSc). We investigated the performance of ScleroID in patients with diffuse cutaneous SSc (dcSSc), as a prerequisite for its use in randomised controlled trials (RCTs) testing potentially disease-modifying drugs. Methods All patients with dcSSc from the large, multicentric, ScleroID cohort were included. SSc-Health Assessment Questionnaire (HAQ), EuroQol-5 Dimensions and 36-item Short Form Health Survey (SF-36) were used as comparators. The study includes a longitudinal arm with a reliability visit at 7±3 days and a 12 months follow-up visit. The performance of ScleroID in dcSSc was assessed according to the Outcome Measures in Rheumatology filter. Results In total, 152 dcSSc patients were analysed (29% male, median age 54 years). ScleroID reflected well the disease impact of dcSSc, showing a good construct validity with high Spearman’s correlation coefficients with comparators (SSc-HAQ, 0.79, 95% CI (0.69, 0.86); HAQ-Disability Index, 0.72 95% CI (0.60, 0.80); SF-36 physical score, −0.69 95% CI (−0.77, –0.60)). The internal consistency was strong (Cronbach’s alpha 0.87, split-half reliability coefficient 0.88). In the longitudinal arm, 44 patients had a reliability visit and 113 had a follow-up visit, of whom 19/113 (17%) reported a significant change (11 improved, 8 worsened). ScleroID showed a good consistency and discriminative ability with excellent test–retest reliability (intraclass correlation coefficient 0.89, 95% CI (0.84, 0.92)) and moderate sensitivity to change (standardised response mean −0.63 in the improved subgroup and 0.48 in the worsened subgroup), but superior to the comparators. Conclusion The European Alliance of Associations for Rheumatology (EULAR) ScleroID performs well for patients with dcSSc. This supports its inclusion and regular assessment as PROM in RCTs.
Open AccessPerformance of the EULAR Systemic sclerosis Impact of Disease (ScleroID) questionnaire as a patient-reported outcome measure for patients with diffuse systemic sclerosis
Objective Systemic sclerosis Impact of Disease (ScleroID) is the first comprehensive patient-reported outcome measure (PROM) specifically developed for systemic sclerosis (SSc). We investigated the performance of ScleroID in patients with diffuse cutaneous SSc (dcSSc), as a prerequisite for its use in randomised controlled trials (RCTs) testing potentially disease-modifying drugs. Methods All patients with dcSSc from the large, multicentric, ScleroID cohort were included. SSc-Health Assessment Questionnaire (HAQ), EuroQol-5 Dimensions and 36-item Short Form Health Survey (SF-36) were used as comparators. The study includes a longitudinal arm with a reliability visit at 7±3 days and a 12 months follow-up visit. The performance of ScleroID in dcSSc was assessed according to the Outcome Measures in Rheumatology filter. Results In total, 152 dcSSc patients were analysed (29% male, median age 54 years). ScleroID reflected well the disease impact of dcSSc, showing a good construct validity with high Spearman’s correlation coefficients with comparators (SSc-HAQ, 0.79, 95% CI (0.69, 0.86); HAQ-Disability Index, 0.72 95% CI (0.60, 0.80); SF-36 physical score, −0.69 95% CI (−0.77, –0.60)). The internal consistency was strong (Cronbach’s alpha 0.87, split-half reliability coefficient 0.88). In the longitudinal arm, 44 patients had a reliability visit and 113 had a follow-up visit, of whom 19/113 (17%) reported a significant change (11 improved, 8 worsened). ScleroID showed a good consistency and discriminative ability with excellent test–retest reliability (intraclass correlation coefficient 0.89, 95% CI (0.84, 0.92)) and moderate sensitivity to change (standardised response mean −0.63 in the improved subgroup and 0.48 in the worsened subgroup), but superior to the comparators. Conclusion The European Alliance of Associations for Rheumatology (EULAR) ScleroID performs well for patients with dcSSc. This supports its inclusion and regular assessment as PROM in RCTs.
- Open Access
- 5 November 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e62877
Noninvasive, Multimodal Inflammatory Biomarker Discovery for Systemic Inflammation (NOVA Study): Protocol for a Cross-Sectional Study
Background: Prolonged systemic inflammation is recognized as a major contributor to the development of various chronic inflammatory diseases. Daily measurements of inflammatory biomarkers can significantly improve disease monitoring of systemic inflammation, thus contributing to reducing the burden on patients and the health care system. There exists, however, no scalable, cost-efficient, and noninvasive biomarker for remote assessment of systemic inflammation. To this end, we propose a novel, multimodal, and noninvasive approach for measuring inflammatory biomarkers. Objective: This study aimed to evaluate the relationship between the levels of inflammatory biomarkers in serum (gold standard) and those measured noninvasively in urine, sweat, saliva, exhaled breath, stool, and core body temperature in patients with systemic inflammation. Methods: This study is a single-center, cross-sectional study and includes a total of 20 participants (10 patients with systemic inflammation and 10 control patients). Eligible participants provide serum, urine, sweat, saliva, exhaled breath, and stool samples for biomarker analyses. Core body temperature is measured using a sensor. The primary end point is the level of C-reactive protein (CRP). The secondary end points are interleukin (IL)–1β, IL-6, IL-8, IL-10, and tumor necrosis factor-α levels. The tertiary end points are fractional exhaled nitric oxide, calprotectin, and core body temperature. Samples will be collected in 2 batches, enabling preliminary analysis of the first batch (patients 1-5 from each group). The full analysis will include both batches. CRP and cytokine levels will be measured using enzyme-linked immunosorbent assay and electrochemiluminescence immunoassay. For statistical analysis, the Shapiro-Wilk test will be used to evaluate the normality of the distribution in each variable. We will perform the 2-tailed t test or Wilcoxon rank sum test to compare the levels of inflammatory biomarkers between patients with systemic inflammations and control patients. Pearson and Spearman correlation coefficients will assess the relationship between inflammatory biomarkers from noninvasive methods and serum biomarkers. Using all-subset regression analysis, we will determine the combination of noninvasive methods yielding the highest predictive accuracy for serum CRP levels. Participants’ preferences for sampling methods will be assessed through a questionnaire. Results: The study received ethics approval from the independent research ethics committee of Canton Zurich on October 28, 2022. A total of 20 participants participated in the study measurements. Data collection started on February 22, 2023, and was completed on September 22, 2023. Participants were on average 52.8 (SD 14.4; range 24-82) years of age, and 70% (14/20) of them were women. The analysis results reporting findings are expected to be published in 2025. Conclusions: This study aims to evaluate the feasibility of noninvasive, multimodal assessment of inflammatory biomarkers in patients with systemic inflammation. Promising results could lead to the creation of noninvasive and potentially digital biomarkers for systemic inflammation, enabling continuous monitoring and early diagnosis of inflammatory activity in a remote setting. International Registered Report Identifier (IRRID): DERR1-10.2196/62877
- 5 November 2024
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 13 (1) , e62877
Open AccessNoninvasive, Multimodal Inflammatory Biomarker Discovery for Systemic Inflammation (NOVA Study): Protocol for a Cross-Sectional Study
Background: Prolonged systemic inflammation is recognized as a major contributor to the development of various chronic inflammatory diseases. Daily measurements of inflammatory biomarkers can significantly improve disease monitoring of systemic inflammation, thus contributing to reducing the burden on patients and the health care system. There exists, however, no scalable, cost-efficient, and noninvasive biomarker for remote assessment of systemic inflammation. To this end, we propose a novel, multimodal, and noninvasive approach for measuring inflammatory biomarkers. Objective: This study aimed to evaluate the relationship between the levels of inflammatory biomarkers in serum (gold standard) and those measured noninvasively in urine, sweat, saliva, exhaled breath, stool, and core body temperature in patients with systemic inflammation. Methods: This study is a single-center, cross-sectional study and includes a total of 20 participants (10 patients with systemic inflammation and 10 control patients). Eligible participants provide serum, urine, sweat, saliva, exhaled breath, and stool samples for biomarker analyses. Core body temperature is measured using a sensor. The primary end point is the level of C-reactive protein (CRP). The secondary end points are interleukin (IL)–1β, IL-6, IL-8, IL-10, and tumor necrosis factor-α levels. The tertiary end points are fractional exhaled nitric oxide, calprotectin, and core body temperature. Samples will be collected in 2 batches, enabling preliminary analysis of the first batch (patients 1-5 from each group). The full analysis will include both batches. CRP and cytokine levels will be measured using enzyme-linked immunosorbent assay and electrochemiluminescence immunoassay. For statistical analysis, the Shapiro-Wilk test will be used to evaluate the normality of the distribution in each variable. We will perform the 2-tailed t test or Wilcoxon rank sum test to compare the levels of inflammatory biomarkers between patients with systemic inflammations and control patients. Pearson and Spearman correlation coefficients will assess the relationship between inflammatory biomarkers from noninvasive methods and serum biomarkers. Using all-subset regression analysis, we will determine the combination of noninvasive methods yielding the highest predictive accuracy for serum CRP levels. Participants’ preferences for sampling methods will be assessed through a questionnaire. Results: The study received ethics approval from the independent research ethics committee of Canton Zurich on October 28, 2022. A total of 20 participants participated in the study measurements. Data collection started on February 22, 2023, and was completed on September 22, 2023. Participants were on average 52.8 (SD 14.4; range 24-82) years of age, and 70% (14/20) of them were women. The analysis results reporting findings are expected to be published in 2025. Conclusions: This study aims to evaluate the feasibility of noninvasive, multimodal assessment of inflammatory biomarkers in patients with systemic inflammation. Promising results could lead to the creation of noninvasive and potentially digital biomarkers for systemic inflammation, enabling continuous monitoring and early diagnosis of inflammatory activity in a remote setting. International Registered Report Identifier (IRRID): DERR1-10.2196/62877
- Open Access
Does therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?
Objectives While important progress was made regarding the treatment of systemic sclerosis (SSc), there is still no evidence-based disease-modifying treatment available for SSc-related gastrointestinal (GI) manifestations. We aimed to identify an association between immunosuppressive therapy and the the severity of GI symptoms, measured by the University of California at Los Angeles/Scleroderma Clinical Trial Consortium Gastro-Intestinal Tract instrument 2.0 (GIT). Methods We selected patients with SSc who had at least two visits (further referred to as ‘baseline’ and ‘follow-up’) with completed GITs, within an interval of 12±3 months. The study outcome was the GIT score at follow-up. We used multivariable linear regression with the following covariates: immunosuppressive therapy during observation, immunosuppressive therapy before baseline, baseline GIT and several baseline parameters selected by clinical judgement as potentially influencing GI symptoms. Results We included 209 SSc patients (82.3% female, median age 59.0 years, median disease duration 6.0 years, 40 (19.1%) diffuse cutaneous SSc, median baseline GIT 0.19). Of these, 71 were exposed to immunosuppressive therapy during the observation period, and, compared with unexposed patients, had overall more severe SSc and a higher prevalence of treatment with proton pump inhibitors. In multivariable linear regression, immunosuppressive therapy during the period of observation and lower baseline GIT scores were significantly associated with lower (better) GIT scores at follow-up. Conclusion Immunosuppressive treatment was associated with lower GIT scores in our cohort, which suggests the potential effects of immunosuppressants on GI manifestations in patients with SSc, requiring confirmation in prospective randomised clinical trials.
Open AccessDoes therapy with immunosuppressive drugs improve gastrointestinal symptoms in patients with systemic sclerosis?
Objectives While important progress was made regarding the treatment of systemic sclerosis (SSc), there is still no evidence-based disease-modifying treatment available for SSc-related gastrointestinal (GI) manifestations. We aimed to identify an association between immunosuppressive therapy and the the severity of GI symptoms, measured by the University of California at Los Angeles/Scleroderma Clinical Trial Consortium Gastro-Intestinal Tract instrument 2.0 (GIT). Methods We selected patients with SSc who had at least two visits (further referred to as ‘baseline’ and ‘follow-up’) with completed GITs, within an interval of 12±3 months. The study outcome was the GIT score at follow-up. We used multivariable linear regression with the following covariates: immunosuppressive therapy during observation, immunosuppressive therapy before baseline, baseline GIT and several baseline parameters selected by clinical judgement as potentially influencing GI symptoms. Results We included 209 SSc patients (82.3% female, median age 59.0 years, median disease duration 6.0 years, 40 (19.1%) diffuse cutaneous SSc, median baseline GIT 0.19). Of these, 71 were exposed to immunosuppressive therapy during the observation period, and, compared with unexposed patients, had overall more severe SSc and a higher prevalence of treatment with proton pump inhibitors. In multivariable linear regression, immunosuppressive therapy during the period of observation and lower baseline GIT scores were significantly associated with lower (better) GIT scores at follow-up. Conclusion Immunosuppressive treatment was associated with lower GIT scores in our cohort, which suggests the potential effects of immunosuppressants on GI manifestations in patients with SSc, requiring confirmation in prospective randomised clinical trials.